{"entity":{"id":"inxmed","kind":"company","name":"InxMed","aka":["InxMed (Shanghai) Co., Ltd.","应世生物","InxMed (Shanghai)","inxmed-shanghai"],"tldr":"InxMed is a Shanghai biotechnology company developing IN10018 (ifebemtinib), a focal adhesion kinase inhibitor, which is in a phase 3 trial with the KRAS G12C inhibitor garsorasib against standard therapy in KRAS G12C-mutant lung cancer.","summary":"InxMed, based in Shanghai, develops drugs against the tumour microenvironment and drug resistance. Its lead candidate IN10018 (ifebemtinib) inhibits focal adhesion kinase (FAK), a signal that helps tumours resist KRAS inhibitors and chemotherapy, and is being tested in a phase 3 trial combined with the KRAS G12C inhibitor D-1553 (garsorasib) against standard therapy in non-small-cell lung cancer, as well as in platinum-resistant ovarian cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.inxmed.com/"},{"label":"ClinicalTrials.gov: trials led by InxMed","url":"https://clinicaltrials.gov/search?lead=InxMed"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","ovarian","pancreatic","sclc"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["in10018"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07174908","nct05994131","nct05827796","nct06014528","nct06030258","nct05551507"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.inxmed.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/inxmed/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"}],"trial":[{"id":"nct07174908","kind":"trial","name":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07174908/"},{"id":"nct05994131","kind":"trial","name":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","route":"/trials/nct05994131/"},{"id":"nct06030258","kind":"trial","name":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC","route":"/trials/nct06030258/"},{"id":"nct06014528","kind":"trial","name":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren","route":"/trials/nct06014528/"},{"id":"nct05551507","kind":"trial","name":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer","route":"/trials/nct05551507/"},{"id":"nct05827796","kind":"trial","name":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer","route":"/trials/nct05827796/"}]}}